| Psoriasis vulgaris

Duobrii vs Renflexis

Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.
Deep comparison between: Duobrii vs Renflexis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsRenflexis has a higher rate of injection site reactions vs Duobrii based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Renflexis but not Duobrii, including UnitedHealthcare
Sign up to reveal the full AI analysis
Duobrii
Renflexis
At A Glance
Topical
Once daily
Corticosteroid/retinoid combination
IV infusion
Every 6-8 weeks
TNF-alpha antagonist
Indications
  • Psoriasis vulgaris
  • Crohn Disease
  • Ulcerative Colitis
  • Rheumatoid Arthritis
  • Ankylosing spondylitis
  • Arthritis, Psoriatic
  • Psoriasis vulgaris
Dosing
Psoriasis vulgaris Apply a thin layer once daily to affected areas, rubbing in gently; total dosage should not exceed approximately 50 g per week; avoid application on the face, groin, or axillae; do not use with occlusive dressings unless directed by a physician; discontinue when control is achieved.
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks; pediatric patients >= 6 years with Crohn Disease or Ulcerative Colitis receive the same regimen.
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete response.
Ankylosing spondylitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 6 weeks.
Contraindications
  • Pregnancy
  • Doses >5 mg/kg in patients with moderate or severe heart failure
  • Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of RENFLEXIS, or any murine proteins
Adverse Reactions
Most common (>=1%) contact dermatitis, application site pain, folliculitis, skin atrophy, excoriation, rash, skin abrasion, skin exfoliation
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis), hepatotoxicity, malignancies, severe infusion reactions
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction
Pharmacology
Combination of halobetasol propionate, a synthetic corticosteroid that modulates cellular signaling, immune function, and inflammation, and tazarotene, a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds RAR-beta and RAR-gamma receptors to modify gene expression; precise mechanisms in plaque psoriasis are unknown.
TNF-alpha antagonist; infliximab-abda is a chimeric IgG1kappa monoclonal antibody that neutralizes TNF-alpha by binding with high affinity to soluble and transmembrane forms of TNF-alpha, inhibiting receptor binding and suppressing downstream pro-inflammatory activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Duobrii
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
View full coverage details ›
Renflexis
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
View full coverage details ›
UnitedHealthcare
Duobrii
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
View full coverage details ›
Renflexis
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Humana
Duobrii
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
View full coverage details ›
Renflexis
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Duobrii.
No savings programs available for Renflexis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
DuobriiView full Duobrii profile
RenflexisView full Renflexis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.